Module 1 — Foundational Principles & General
Pharmacology
Advanced Prac ce Nursing / NP-Level Prac ce Quiz: 50 Original Case-Based
Ques ons
Scope: Pharmacokine cs (ADME), pharmacodynamics, therapeu c index, half-life/steady state,
medica on safety, and prescrip on requirements.
Level: MSN/NP / na onal board-style.
Design: All scenarios, ques ons, answer choices, and ra onales are newly wri en and based on
generalized pharmacology principles rather than any specific commercial ques on bank or
textbook.
Ques on 1 — First-Pass Metabolism and Oral Bioavailability
A 58-year-old man with hypertension is prescribed an oral medica on that undergoes extensive
hepa c first-pass metabolism. A er several weeks of therapy, he develops nausea and dizziness
whenever his dose is increased. The clinician considers changing the medica on to a sublingual
formula on to obtain a more predictable systemic effect.
Which pharmacokine c principle best explains why the sublingual route may produce greater
systemic bioavailability?
A. Sublingual administra on increases renal tubular reabsorp on.
B. Sublingual administra on bypasses much of the gastrointes nal and hepa c first-pass effect.
C. Sublingual administra on increases plasma protein binding.
D. Sublingual administra on prolongs drug elimina on by reducing glomerular filtra on.
Correct Answer: B
Clinical Ra onale
,The absolute priority concept is first-pass metabolism. An orally administered drug enters the
gastrointes nal tract, is absorbed through the intes nal mucosa, and then reaches the portal
circula on before systemic circula on. A drug with substan al hepa c first-pass metabolism
may have a significant frac on metabolized before it reaches its systemic target. A sublingual
medica on can enter systemic circula on through oral mucosal vessels and thereby largely
bypass gastrointes nal absorp on and hepa c first-pass metabolism, increasing effec ve
bioavailability and o en reducing variability in exposure.
A. Incorrect: Renal tubular reabsorp on affects elimina on, not the primary reason sublingual
administra on improves bioavailability.
C. Incorrect: Plasma protein binding influences distribu on and free-drug concentra on but
does not explain bypass of hepa c first-pass metabolism.
D. Incorrect: Glomerular filtra on is part of renal elimina on and is unrelated to the route-
dependent first-pass effect.
Clinical applica on: When an oral medica on has substan al first-pass metabolism, changing
the route can meaningfully alter the dose required to achieve a therapeu c systemic
concentra on.
Ques on 2 — Absorp on and Gastric pH
A 72-year-old woman takes a medica on whose absorp on depends partly on an acidic gastric
environment. She begins chronic therapy with a potent acid-suppressing agent. Several weeks
later, her therapeu c response diminishes despite documented adherence.
Which pharmacokine c change is most likely responsible?
A. Increased renal clearance caused by lower gastric acidity
B. Reduced gastrointes nal absorp on caused by altered gastric pH
C. Increased hepa c protein synthesis reducing drug metabolism
D. Increased plasma protein binding caused by alkaline gastric contents
,Correct Answer: B
Clinical Ra onale
The most likely mechanism is altered absorp on secondary to increased gastric pH. Some
drugs depend on gastric acidity for dissolu on or ioniza on condi ons that facilitate absorp on.
Raising gastric pH can decrease dissolu on or alter the frac on available for intes nal uptake,
thereby reducing systemic drug exposure.
A. Incorrect: Gastric pH does not directly determine renal clearance.
C. Incorrect: Hepa c protein synthesis is unrelated to the immediate effect of gastric acid
suppression on drug absorp on.
D. Incorrect: Plasma protein binding occurs primarily a er systemic entry and does not depend
directly on gastric pH.
Clinical applica on: When a pa ent experiences an unexpected loss of efficacy a er star ng
acid-suppressive therapy, consider a pharmacokine c absorp on interac on rather than
immediately escala ng the dose.
Ques on 3 — Protein Binding and Free Drug
A 64-year-old pa ent with advanced liver disease has marked hypoalbuminemia. She begins
therapy with a medica on that is normally 98% bound to plasma albumin. Shortly a er
ini a on, she develops seda on and impaired coordina on despite receiving a standard dose.
Which pharmacokine c change most likely explains her increased toxicity?
A. Decreased hepa c blood flow always decreases the unbound drug frac on.
B. Reduced albumin concentra on increases the propor on of unbound drug.
C. Hypoalbuminemia causes complete gastrointes nal malabsorp on.
D. Reduced albumin causes increased renal protein synthesis.
Correct Answer: B
, Clinical Ra onale
The clinically important concept is free versus bound drug. Only the unbound frac on is
generally available to cross membranes, reach receptors, undergo hepa c metabolism, and
undergo glomerular filtra on. A highly protein-bound medica on in a pa ent with substan ally
reduced albumin may have a greater free frac on, increasing pharmacologic ac vity and
toxicity even though the total measured plasma concentra on may appear acceptable.
A. Incorrect: Decreased hepa c blood flow can influence clearance, but it does not inherently
decrease the unbound frac on.
C. Incorrect: Albumin concentra on does not determine gastrointes nal absorp on in this
manner.
D. Incorrect: The kidneys do not synthesize albumin in a way that would correct the
pharmacokine c problem.
Clinical applica on: In severe hypoalbuminemia, therapeu c drug monitoring based solely on
total concentra on may be misleading for highly protein-bound drugs.
Ques on 4 — Distribu on and Volume of Distribu on
A 46-year-old woman receives an intravenous medica on that rapidly leaves the vascular
compartment and distributes extensively into adipose and other ssues. Her measured plasma
concentra on falls rapidly during the early phase a er administra on.
Which parameter most directly describes the apparent extent of this distribu on?
A. Clearance
B. Half-life
C. Volume of distribu on
D. Bioavailability
Correct Answer: C
Pharmacology
Advanced Prac ce Nursing / NP-Level Prac ce Quiz: 50 Original Case-Based
Ques ons
Scope: Pharmacokine cs (ADME), pharmacodynamics, therapeu c index, half-life/steady state,
medica on safety, and prescrip on requirements.
Level: MSN/NP / na onal board-style.
Design: All scenarios, ques ons, answer choices, and ra onales are newly wri en and based on
generalized pharmacology principles rather than any specific commercial ques on bank or
textbook.
Ques on 1 — First-Pass Metabolism and Oral Bioavailability
A 58-year-old man with hypertension is prescribed an oral medica on that undergoes extensive
hepa c first-pass metabolism. A er several weeks of therapy, he develops nausea and dizziness
whenever his dose is increased. The clinician considers changing the medica on to a sublingual
formula on to obtain a more predictable systemic effect.
Which pharmacokine c principle best explains why the sublingual route may produce greater
systemic bioavailability?
A. Sublingual administra on increases renal tubular reabsorp on.
B. Sublingual administra on bypasses much of the gastrointes nal and hepa c first-pass effect.
C. Sublingual administra on increases plasma protein binding.
D. Sublingual administra on prolongs drug elimina on by reducing glomerular filtra on.
Correct Answer: B
Clinical Ra onale
,The absolute priority concept is first-pass metabolism. An orally administered drug enters the
gastrointes nal tract, is absorbed through the intes nal mucosa, and then reaches the portal
circula on before systemic circula on. A drug with substan al hepa c first-pass metabolism
may have a significant frac on metabolized before it reaches its systemic target. A sublingual
medica on can enter systemic circula on through oral mucosal vessels and thereby largely
bypass gastrointes nal absorp on and hepa c first-pass metabolism, increasing effec ve
bioavailability and o en reducing variability in exposure.
A. Incorrect: Renal tubular reabsorp on affects elimina on, not the primary reason sublingual
administra on improves bioavailability.
C. Incorrect: Plasma protein binding influences distribu on and free-drug concentra on but
does not explain bypass of hepa c first-pass metabolism.
D. Incorrect: Glomerular filtra on is part of renal elimina on and is unrelated to the route-
dependent first-pass effect.
Clinical applica on: When an oral medica on has substan al first-pass metabolism, changing
the route can meaningfully alter the dose required to achieve a therapeu c systemic
concentra on.
Ques on 2 — Absorp on and Gastric pH
A 72-year-old woman takes a medica on whose absorp on depends partly on an acidic gastric
environment. She begins chronic therapy with a potent acid-suppressing agent. Several weeks
later, her therapeu c response diminishes despite documented adherence.
Which pharmacokine c change is most likely responsible?
A. Increased renal clearance caused by lower gastric acidity
B. Reduced gastrointes nal absorp on caused by altered gastric pH
C. Increased hepa c protein synthesis reducing drug metabolism
D. Increased plasma protein binding caused by alkaline gastric contents
,Correct Answer: B
Clinical Ra onale
The most likely mechanism is altered absorp on secondary to increased gastric pH. Some
drugs depend on gastric acidity for dissolu on or ioniza on condi ons that facilitate absorp on.
Raising gastric pH can decrease dissolu on or alter the frac on available for intes nal uptake,
thereby reducing systemic drug exposure.
A. Incorrect: Gastric pH does not directly determine renal clearance.
C. Incorrect: Hepa c protein synthesis is unrelated to the immediate effect of gastric acid
suppression on drug absorp on.
D. Incorrect: Plasma protein binding occurs primarily a er systemic entry and does not depend
directly on gastric pH.
Clinical applica on: When a pa ent experiences an unexpected loss of efficacy a er star ng
acid-suppressive therapy, consider a pharmacokine c absorp on interac on rather than
immediately escala ng the dose.
Ques on 3 — Protein Binding and Free Drug
A 64-year-old pa ent with advanced liver disease has marked hypoalbuminemia. She begins
therapy with a medica on that is normally 98% bound to plasma albumin. Shortly a er
ini a on, she develops seda on and impaired coordina on despite receiving a standard dose.
Which pharmacokine c change most likely explains her increased toxicity?
A. Decreased hepa c blood flow always decreases the unbound drug frac on.
B. Reduced albumin concentra on increases the propor on of unbound drug.
C. Hypoalbuminemia causes complete gastrointes nal malabsorp on.
D. Reduced albumin causes increased renal protein synthesis.
Correct Answer: B
, Clinical Ra onale
The clinically important concept is free versus bound drug. Only the unbound frac on is
generally available to cross membranes, reach receptors, undergo hepa c metabolism, and
undergo glomerular filtra on. A highly protein-bound medica on in a pa ent with substan ally
reduced albumin may have a greater free frac on, increasing pharmacologic ac vity and
toxicity even though the total measured plasma concentra on may appear acceptable.
A. Incorrect: Decreased hepa c blood flow can influence clearance, but it does not inherently
decrease the unbound frac on.
C. Incorrect: Albumin concentra on does not determine gastrointes nal absorp on in this
manner.
D. Incorrect: The kidneys do not synthesize albumin in a way that would correct the
pharmacokine c problem.
Clinical applica on: In severe hypoalbuminemia, therapeu c drug monitoring based solely on
total concentra on may be misleading for highly protein-bound drugs.
Ques on 4 — Distribu on and Volume of Distribu on
A 46-year-old woman receives an intravenous medica on that rapidly leaves the vascular
compartment and distributes extensively into adipose and other ssues. Her measured plasma
concentra on falls rapidly during the early phase a er administra on.
Which parameter most directly describes the apparent extent of this distribu on?
A. Clearance
B. Half-life
C. Volume of distribu on
D. Bioavailability
Correct Answer: C
